Ofatumumab versus Teriflunomide in Multiple Sclerosis von Hauser, Stephen L, Bar-Or, Amit, Cohen, Jeffrey A, Comi, Giancarlo, Correale, Jorge, Coyle, Patricia K, Cross, Anne H, de Seze, Jerome, Leppert, David, Montalban, Xavier, Selmaj, Krzysztof, Wiendl, Heinz, Kerloeguen, Cecile, Willi, Roman, Li, Bingbing, Kakarieka, Algirdas, Tomic, Davorka, Goodyear, Alexandra, Pingili, Ratnakar, Häring, Dieter A, Ramanathan, Krishnan, Merschhemke, Martin, Kappos, Ludwig

Volltext

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis von Chitnis, Tanuja, Arnold, Douglas L, Banwell, Brenda, Brück, Wolfgang, Ghezzi, Angelo, Giovannoni, Gavin, Greenberg, Benjamin, Krupp, Lauren, Rostásy, Kevin, Tardieu, Marc, Waubant, Emmanuelle, Wolinsky, Jerry S, Bar-Or, Amit, Stites, Tracy, Chen, Yu, Putzki, Norman, Merschhemke, Martin, Gärtner, Jutta

Volltext

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial von Lublin, Fred, Prof, Miller, David H, Prof, Freedman, Mark S, Prof, Cree, Bruce A C, Prof, Wolinsky, Jerry S, Prof, Weiner, Howard, Prof, Lubetzki, Catherine, Prof, Hartung, Hans-Peter, Prof, Montalban, Xavier, Prof, Uitdehaag, Bernard M J, Prof, Merschhemke, Martin, MD, Li, Bingbing, PhD, Putzki, Norman, MD, Liu, Fonda C, PharmD, Häring, Dieter A, PhD, Kappos, Ludwig, Prof

Volltext

Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study von Kira, Jun-ichi, Nakahara, Jin, Sazonov, Denis V, Kurosawa, Takayoshi, Tsumiyama, Isao, Willi, Roman, Zalesak, Martin, Pingili, Ratnakar, Häring, Dieter A, Ramanathan, Krishnan, Kieseier, Bernd C, Merschhemke, Martin, Su, Wendy, Saida, Takahiko

Volltext

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study von Bar-Or, Amit, Wiendl, Heinz, Montalban, Xavier, Alvarez, Enrique, Davydovskaya, Maria, Delgado, Silvia R, Evdoshenko, Evgeniy P, Giedraitiene, Natasa, Gross-Paju, Katrin, Haldre, Sulev, Herrman, Craig E, Izquierdo, Guillermo, Karelis, Guntis, Leutmezer, Fritz, Mares, Miroslav, Meca-Lallana, Jose E, Mickeviciene, Dalia, Nicholas, Jacqueline, Robertson, Derrick S, Sazonov, Denis V, Sharlin, Kenneth, Sundaram, Bharathy, Totolyan, Natalia, Vachova, Marta, Valis, Martin, Bagger, Morten, Häring, Dieter A, Ludwig, Inga, Willi, Roman, Zalesak, Martin, Su, Wendy, Merschhemke, Martin, Fox, Edward J

Volltext

A new clinico-pathological classification system for mesial temporal sclerosis von Blümcke, Ingmar, Pauli, Elisabeth, Clusmann, Hans, Schramm, Johannes, Becker, Albert, Elger, Christian, Merschhemke, Martin, Meencke, Heinz-Joachim, Lehmann, Thomas, von Deimling, Andreas, Scheiwe, Christian, Zentner, Josef, Volk, Benedikt, Romstöck, Johann, Stefan, Hermann, Hildebrandt, Michelle

Volltext

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Tr... von Ziemssen, Tjalf, Arnold, Douglas L, Alvarez, Enrique, Cross, Anne H, Willi, Roman, Li, Bingbing, Kukkaro, Petra, Kropshofer, Harald, Ramanathan, Krishnan, Merschhemke, Martin, Kieseier, Bernd, Su, Wendy, Häring, Dieter A, Hauser, Stephen L, Kappos, Ludwig, Kuhle, Jens

Volltext

The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment von Hauser, Stephen L., Kappos, Ludwig, Bar-Or, Amit, Wiendl, Heinz, Paling, David, Williams, Mitzi, Gold, Ralf, Chan, Andrew, Milo, Ron, Das Gupta, Ayan, Karlsson, Goeril, Sullivan, Roseanne, Graham, Gordon, Merschhemke, Martin, Häring, Dieter A., Vermersch, Patrick

Volltext

Comparative efficacy of ofatumumab versus oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons von Riley, Nicholas, Drudge, Christopher, Nelson, Morag, Haltner, Anja, Barnett, Michael, Broadley, Simon, Butzkueven, Helmut, McCombe, Pamela, Van der Walt, Anneke, Wong, Erin O. Y., Merschhemke, Martin, Adlard, Nicholas, Walker, Rob, Samjoo, Imtiaz A.

Volltext

2967 Utilisation of high efficacy therapy for managing multiple sclerosis in Australia von McCombe, Pamela, Butzkueven, Helmut, Samjoo, Imtiaz, Barnett, Michael, Broadley, Simon, Walt, Anneke Van der, Merschhemke, Martin, Adlard, Nicholas, Burke, Naomi, Riley, Nicholas, Walker, Rob

Volltext

Towards a clinico-pathological classification of granule cell dispersion in human mesial temporal lobe epilepsies von Blümcke, Ingmar, Kistner, Iris, Clusmann, Hans, Schramm, Johannes, Becker, Albert J., Elger, Christian E., Bien, Christian G., Merschhemke, Martin, Meencke, Heinz-Joachim, Lehmann, Thomas, Buchfelder, Michael, Weigel, Daniel, Buslei, Rolf, Stefan, Hermann, Pauli, Elisabeth, Hildebrandt, Michelle

Volltext

A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo von Vermersch, Patrick, Radue, Ernst-Wilhelm, Putzki, Norman, Ritter, Shannon, Merschhemke, Martin, Freedman, Mark S

Volltext

Progressive multifocal leukoencephalopathy after fingolimod treatment von Berger, Joseph R, Cree, Bruce A, Greenberg, Benjamin, Hemmer, Bernhard, Ward, Brian J, Dong, Victor M, Merschhemke, Martin

Volltext

Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation von Merschhemke, Martin, Tomic, Davorka, Putzki, Norman

Volltext

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study von Stocchi, Fabrizio, Rascol, Olivier, Destee, Alain, Hattori, Nobutaka, Hauser, Robert A., Lang, Anthony E., Poewe, Werner, Stacy, Mark, Tolosa, Eduardo, Gao, Haitao, Nagel, Jennifer, Merschhemke, Martin, Graf, Ana, Kenney, Christopher, Trenkwalder, Claudia

Volltext

Onset of B-cell Depletion and Suppression of MRI Activity with Ofatumumab Treatment in Relapsing Multiple Sclerosis: The APLIOS Study (3971) von Bar-Or, Amit, Fox, Edward, Goodyear, Alexandra, Ludwig, Inga, Bagger, Morten, Häring, Dieter A., Kropshofer, Harald, Merschhemke, Martin, Wiendl, Heinz

Volltext

Ofatumumab Reduces Disability Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis (1845) von Montalban, Xavier, Cohen, Jeffrey A., Comi, Giancarlo, Coyle, Patricia K., Kappos, Ludwig, Li, Bingbing, Sfikas, Nikolaos, Willi, Roman, Häring, Dieter A., Merschhemke, Martin, Hauser, Stephen L.

Volltext

Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial von Hughes, Richard, Dalakas, Marinos C, Merkies, Ingemar, Latov, Norman, Léger, Jean-Marc, Nobile-Orazio, Eduardo, Sobue, Gen, Genge, Angela, Cornblath, David, Merschhemke, Martin, Ervin, Carolyn Marie, Agoropoulou, Catherine, Hartung, Hans-Peter, Day, Timothy, Spies, Judith, Roberts, Leslie, Van Damme, Philip, Van den Bergh, Peter YK, Maertens de Noordhout, Alain, Dionne, Annie, Larue, Sandrine, Massie, Rami, Melanson, Michel, Camu, William, De Seze, Jérôme, Le Masson, Gwendal, Pouget, Jean, Schmidt, Jens, Kimiskidis, Vasilios K, Chapman, Joab, Drory, Vivian E, Fazio, Raffaella, Gallia, Francesca, Kusunoki, Susumu, Mori, Masahiro, Iijima, Masahiro, Okamoto, Tomoko, Baba, Masayuki, Faber, Catharina G, van Schaik, Ivo N, Fryze, Waldemar, Motta, Ewa, Selmaj, Krzysztof, Casasnovas, Carlos, Sola, Antonio Guerrero, Illa, Isabel, Holt, James, Miller, James AL, Lunn, Michael P, Brannagan, Thomas H, Brown, Martin, Kelemen, John, Iyadurai, Stanley, Rezania, Kourosh, Sharma, Khema R, Tandan, Rup, Gudesblatt, Mark, Lawson, Victoria, Amato, Anthony A

Volltext

Prognostic Value of Serum NfL for Subclinical Disease Activity and Worsening in Patients with RMS: Results from the Phase 3 ASCLEPIOS I and II Trials (4069) von Ziemssen, Tjalf, Arnold, Douglas L., Alvarez, Enrique, Cross, Anne H., Willi, Roman, Li, Bingbing, Kukkaro, Petra, Kropshofer, Harald, Ramanathan, Krishnan, Merschhemke, Martin, Su, Wendy, Haering, Dieter A., Hauser, Stephen L., Kappos, Ludwig, Kuhle, Jens

Volltext

Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis (RMS) Patients from the Phase 3 ASCLEPIOS I and II Trials (1300) von Bar-Or, Amit, De Seze, Jerome, Correale, Jorge, Cross, Anne, Kappos, Ludwig, Selmaj, Krzysztof, Wiendl, Heinz, Kerloeguen, Cecile, Pingili, Ratnakar, Sullivan, Roseanne, Gupta, Ayan Das, Jehl, Valentine, Haering, Dieter, Merschhemke, Martin, Hauser, Stephen

Volltext